The PE ratio for Ani Pharmaceuticals stock stands at 38.29 as of Jul 25, 2024. This results from the current EPS of $1.62 and stock price of $62.03.
Over the last ten years, the average PE ratio of Ani Pharmaceuticals has been 432.22. The current 38.29 PE ratio is 91% below the historical average. Over the past ten years, ANIP's PE ratio was at its highest in the Jun 2018 quarter at 6,680, with a price of $66.8 and an EPS of $0.01. The Sep 2015 quarter recorded the bottom point at 13.21, with a price of $39.51 and an EPS of $2.99.
Maximum annual increase: 429.36% in 2016
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 64.12 | N/A |
| 2022 | N/A | N/A |
| 2021 | N/A | N/A |
| 2020 | N/A | N/A |
| 2019 | 120.92 | 251.82% |
| 2018 | 34.37 | N/A |
| 2017 | N/A | N/A |
| 2016 | 178.29 | 429.36% |
| 2015 | 33.68 | 55.85% |
| 2014 | 21.61 | N/A |
Currently, ANIP's PE ratio is below the 5 and 10-year averages.
ANIP's PE ratio is lower than its peer stock CAH, but it is greater than NVS's and RPRX's. Ani Pharmaceuticals's current PE ratio of 38.29 is above the average of its peers, which is 23.35.
| Stock name | PE ratio | Market cap |
|---|---|---|
| NVS Novartis AG | 13.96 | $225.1B |
| RPRX Royalty Pharma plc | 16.09 | $17.21B |
| JAZZ Jazz Pharmaceuticals plc | 21.34 | $7.04B |
| ANIP Ani Pharmaceuticals Inc | 39.03 | $1.33B |
| CAH Cardinal Health Inc | 43.14 | $23.95B |
| TEVA Teva Pharmaceutical Industries Ltd | N/A | $19.37B |
| CLDX Celldex Therapeutics Inc | N/A | $2.93B |
| PFE Pfizer Inc | N/A | $174.36B |
ANIP's price to earnings ratio is 38.29 as of Jul 25, 2024.
The 5-year average PE ratio for ANIP stock is 78.09.
Over the last ten years, the quarterly PE ratio reached a historic high of 6,680 in the Jun 2018 quarter.
ANIP's price to earnings ratio is currently 91% below its 10-year historical average.
The PE ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Jul 25, 2024), Ani Pharmaceuticals's stock price is $62.03. The earnings per share for the trailing twelve months (TTM) ending Mar 2024 is $1.62. Therefore, Ani Pharmaceuticals's P/E ratio for today is 38.29. PE RATIO(38.29) = STOCK PRICE($62.03) / TTM EPS($1.62)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.